Hugo Castro Malaspina

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program
    Hugo Castro-Malaspina
    Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Blood 99:1943-51. 2002
  2. ncbi Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings
    Hugo Castro-Malaspina
    The Allogeneic Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Biol Blood Marrow Transplant 14:458-68. 2008
  3. ncbi Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure
    Joseph H Chewning
    Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Biol Blood Marrow Transplant 13:1313-23. 2007
  4. ncbi Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies
    Trudy N Small
    Department of Pediatrics, Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Biol Blood Marrow Transplant 13:235-44. 2007
  5. ncbi T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin
    Ann A Jakubowski
    Adult Allogeneic Bone Marrow Transplant Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10065, USA
    Blood 110:4552-9. 2007
  6. ncbi Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma
    Alison J Moskowitz
    Medical Oncology Hematology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 8, New York, NY 10065, USA
    Br J Haematol 146:158-63. 2009
  7. ncbi Response to pneumococcal (PNCRM7) and haemophilus influenzae conjugate vaccines (HIB) in pediatric and adult recipients of an allogeneic hematopoietic cell transplantation (alloHCT)
    Mary Pao
    Memorial Sloan Kettering, New York, New York 10065, USA
    Biol Blood Marrow Transplant 14:1022-30. 2008
  8. ncbi Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants
    Dana Jaffe
    Department of Pediatrics, Bone Marrow Transplant Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Blood 108:2470-5. 2006
  9. ncbi Sustained complete remission of CLL associated with the use of a Chinese herbal extract: case report and mechanistic analysis
    Traci E Battle
    Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Leuk Res 27:859-63. 2003

Collaborators

Detail Information

Publications9

  1. ncbi Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program
    Hugo Castro-Malaspina
    Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Blood 99:1943-51. 2002
    ..The observations made in this study should facilitate the design of prospective trials aimed at improving the results of unrelated donor stem cell transplantation for MDS...
  2. ncbi Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings
    Hugo Castro-Malaspina
    The Allogeneic Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Biol Blood Marrow Transplant 14:458-68. 2008
    ....
  3. ncbi Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure
    Joseph H Chewning
    Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Biol Blood Marrow Transplant 13:1313-23. 2007
    ....
  4. ncbi Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies
    Trudy N Small
    Department of Pediatrics, Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Biol Blood Marrow Transplant 13:235-44. 2007
    ..For 18 patients with MDS (< or = RAEB-2) or high-risk myeloproliferative disorder, the estimated 3 year DFS is 61%. These data demonstrate the curative potential of this regimen in patients with high-risk myeloid malignancies...
  5. ncbi T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin
    Ann A Jakubowski
    Adult Allogeneic Bone Marrow Transplant Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10065, USA
    Blood 110:4552-9. 2007
    ..Life-threatening OIs occurred in 3 of 52 patients and was fatal in 1. This study demonstrates durable engraftment with a low incidence of GvHD despite the lack of ATG, as well as the curative potential of this regimen...
  6. ncbi Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma
    Alison J Moskowitz
    Medical Oncology Hematology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 8, New York, NY 10065, USA
    Br J Haematol 146:158-63. 2009
    ..Future studies should focus on prospectively evaluating RIT following HDT-ASCT failure in patients with remission duration from HDT-ASCT of >6 months...
  7. ncbi Response to pneumococcal (PNCRM7) and haemophilus influenzae conjugate vaccines (HIB) in pediatric and adult recipients of an allogeneic hematopoietic cell transplantation (alloHCT)
    Mary Pao
    Memorial Sloan Kettering, New York, New York 10065, USA
    Biol Blood Marrow Transplant 14:1022-30. 2008
    ..Prospective, multicenter trials assessing the best strategy to administer this vaccine and its impact on pneumococcal infections following transplantation are warranted...
  8. ncbi Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants
    Dana Jaffe
    Department of Pediatrics, Bone Marrow Transplant Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Blood 108:2470-5. 2006
    ....
  9. ncbi Sustained complete remission of CLL associated with the use of a Chinese herbal extract: case report and mechanistic analysis
    Traci E Battle
    Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Leuk Res 27:859-63. 2003
    ..However, it did not inhibit the activation of Akt or MAP kinase, nor did it inhibit the serine phosphorylation of STAT1. Thus, through an as yet unknown mechanism, this extract appears to exert pro-apoptotic effects in CLL...